Genmab — April 2026

[E_L]

BNP Paribas Upgrades Genmab to Outperform from Neutral, Boosts PT to dkk2.400 (from 1.300)

MT Newswires
·
Apr 22 2026

[JKY_VH]

Sikke et pludseligt klarsyn og god formiddag:-)

[Bella1]

Louis Nielsen har nok åbnet butik i Frankrig

[JKY_VH]

[JKY_VH]

[ProinvestorNEWS]

"The winner takes it all" . Det globale aktiemarked er presset for tiden - men for NASDAQ-indekset i USA kører det forrygende. Der sættes hele tiden nye kursrekorder trods krig, stigende oliepriser osv. Helge Larsen ser på årsagerne og kommer sidst i ugekommentaren også ind på, hvorfor pharma ikke er en sikker havn i disse urolige tider. Kort video: https://proinvestor.com/boards/132062

[E_L]

Petosemtamab Ph3 goes from 500 to 700 patients , same completion dates
https://clinicaltrials.gov/study/NCT06525220

[Sukkeralf]

https://www.fiercebiotech.com/biotech/pfizer-ends-work-phase-1-stage-immunostimulatory-drug-conjugate-cancer-patients

[Sukkeralf]

Nogen der kender til succesrige selskaber indenfor dette felt

[Sukkeralf]

ISACs

[JKY_VH]

Mim8 fra Børsen "Rival skoser udfordrer fra Novo Nordisk". “Vi ser faktisk ikke rigtig nogen klinisk forskel i forhold til Mim8 for at være ærlig,” siger Teresa Graham, adm. direktør for Roche Pharmaceuticals, om de to produkter.", men det skal han jo sige.

[JKY_VH]

"Analytikerne estimerer, at Novo Nordisks produkt når et topsalg på 12 mia. kr. i midten af næste årti – en del under salget af Hemlibra, der nåede tæt på 38 mia. kr. i 2025", skriver Børsen https://borsen.dk/nyheder/virksomheder/rival-skoser-udfordrer-fra-novo-nordisk?b_source=borsen&b_medium=row_0&b_campaign=news_3

[E_L]

@SugarAlf Bolt has the Boltbody ISAC platform which Genmab collaborates on. no signs of success yet i think

[Sukkeralf]

No so far the no promissing results from Bolt and I would think an IND in the Genmab collaboration is a bit overdue or maybe even dropped. But Bolt is cheap so any success could catapult the stock up high

[E_L]

if there is ANY chance of success on one of the Genmab ISAC's they should just buy Bolt at this price...

[E_L]

Novartis Q1 2026 - Kesimpta (USD 1 164 million, +26% cc) sales grew across all regions, driven by increased demand https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf

and strong access. https://www.novartis.com/sites/novartis_com/files/q1-2026-media-release-en.pdf

[Solsen]

Still very impressive !

[Raun]

Så for den da - Der sker noget på den amerikanske notering

[E_L]

AbbVie Q1 2026 Epkinly US $25m + Int 58 = 83 (vs i think $51m Q1 25) https://news.abbvie.com/2026-04-29-AbbVie-Reports-First-Quarter-2026-Financial-Results

[concillado]

Kurs 1.666 - godt man ikke er overtroisk